서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 44 of 44

Issue DateTitle / Author(s) / CitationFileAltmetrics
2005-01
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa (R), ZD1839) in chemotherapy-resistant non-small cell lung cancer
DOI
2005-04
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
DOI
2006-02
CPR or DNR? End-of-life decision in Korean cancer patients: a single center's experience
DOI
2006-07
First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma
DOI
2006-08
First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma
link
2006-11
Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients
DOI
2007-05
Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer
DOI
2008-02
Metastasis-associated protein S100A4 and p53 predict relapse in curatively resected stage III and IV (M0) gastric cancer
DOI
2008-06
ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer
DOI
2008-07
Mucoepidermoid carcinoma of lung: Potential target of EGFR-directed treatment
DOI
2009-07
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI
DOI
2009-07
Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy
DOI
2009-08
Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma
DOI
2009-09
Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement
DOI
2010-03
Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer
DOI
2010-06
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer
DOI
2011-02
Increasing Nodal Ratio is a Poor Prognostic Factor for Survival in Stage III-IV (M0) Gastric Cancer Patients Who Received Curative Surgery Followed by Adjuvant Chemotherapy: A Retrospective Study
DOI
2011-09
Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy
DOI
2011-09
VEGF Expression is Related to Good Response and Long Progression-free Survival in Gastrointestinal Stromal Tumor Patients Treated With Sunitinib
DOI
2012-01
Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment
DOI
2012-02
Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy
DOI
2013-07
Clinical Usefulness of AJCC Response Criteria for Neoadjuvant Chemotherapy in Breast Cancer
DOI
2013-12
Clinical Implications of VEGF, TGF-beta 1, and IL-1 beta in Patients with Advanced Non-small Cell Lung Cancer
DOI
2014-04
Comparison of toxicity of different nanorod-type TiO2 polymorphs in vivo and in vitro

Park, Eun-Jung; Lee, Gwang-Hee; Shim, Hyun-Woo; Kim, Jae-Ho; Cho, Myung-Haing; Kim, Dong-Wan

Journal of Applied Toxicology, Vol.34 No.4, pp.357-366

DOI
2014-10
Sheet-type titania, but not P25, induced paraptosis accompanying apoptosis in murine alveolar macrophage cells
DOI
2014-11
Time-dependent bioaccumulation of distinct rod-type TiO2 nanoparticles: Comparison by crystalline phase
DOI
2015-09
Toxic response of graphene nanoplatelets in vivo and in vitro
DOI
2015-10
Comparison of the toxicity of aluminum oxide nanorods with different aspect ratio
DOI
2016-03
Biodistribution and toxicity of spherical aluminum oxide nanoparticles

Park, Eun-Jung; Lee, Gwang-Hee; Yoon, Cheolho; Jeong, Uiseok; Kim, Younghun; Cho, Myung-Haing; Kim, Dong-Wan

Journal of Applied Toxicology, Vol.36 No.3, pp.424-433

DOI
2018-02
Repeat biopsy of patients with acquired resistance to EGFR TKIs: implications of biopsy-related factors on T790M mutation detection
DOI
2018-07
Phase 1 studies of poziotinib, an irreversible pan-her tyrosine kinase inhibitor in patients with advanced solid tumors
DOI
2020-03
Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis
DOI
2020-07
Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors
DOI
2022-01
Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer
DOI
2022-04
Culture and multiomic analysis of lung cancer patient-derived pleural effusions revealed distinct druggable molecular types
DOI
2022-04
Metal organic framework-based nanostructure materials: applications for non-lithium ion battery electrodes
DOI
2022-06
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
DOI
2022-07
Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis
DOI
2022-09
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
DOI
2022-09
Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer: Results of a phase 2, single-arm, open-label study
DOI
2022-10
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC
DOI
2022-12
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK plus Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
DOI
2022-12
Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations
DOI
2023-10
Prognostic utility of body composition parameters based on computed tomography analysis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors
view fileDOI
1